EGFR and cancer: Kim et al. demonstrate that the combination of circulating and exosomal nucleic acid in the pleural fluid can help evaluate low‐abundant EGFR mutant copies in NSCLC.[219] C‐Met activation increases miR‐130b levels and promotes cancer resistance to hormone ablation therapy.